Insider transactions

EDGAR

GALERA THERAPEUTICS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–21 of 21

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-08-03 Filed 2026-08-05CHANG NANCY T Director · 10% owner
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)47,434——0Direct (D) No
F2, F3, F4
  • F2 These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera effected on July 12, 2026.
  • F3 Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the Merger Agreement), by and among Galera, Obsidian Therapeutics, Inc. (Obsidian), Gazelle Parent, Inc. (Parent), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (Obsidian Merger Sub), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (Galera Merger Sub), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the Galera Merger), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent.
  • F4 At the effective time of the Galera Merger (the Galera Effective Time), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the Galera Exchange Ratio).
Open filing 0001193125-26-335224 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05CHANG NANCY T Director · 10% owner
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (480) — exercise price 8.20
Disposed (D)480——0Direct (D) No
F2, F3, F5
  • F2 These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera effected on July 12, 2026.
  • F3 Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the Merger Agreement), by and among Galera, Obsidian Therapeutics, Inc. (Obsidian), Gazelle Parent, Inc. (Parent), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (Obsidian Merger Sub), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (Galera Merger Sub), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the Galera Merger), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent.
  • F5 At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an In-the-Money Option), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.
Open filing 0001193125-26-335224 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Alleva Lawrence M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)11——0Direct (D) No
F1, F2, F3
  • F1 These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (Galera) effected on July 12, 2026.
  • F2 Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the Merger Agreement), by and among Galera, Obsidian Therapeutics, Inc. (Obsidian), Gazelle Parent, Inc. (Parent), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (Obsidian Merger Sub), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (Galera Merger Sub), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the Galera Merger), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the Mergers).
  • F3 At the effective time of the Galera Merger (the Galera Effective Time), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the Galera Exchange Ratio).
Open filing 0001193125-26-335215 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Alleva Lawrence M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)40——0Indirect (I) By the Lawrence M. Alleva Revocable Trust.No
F1, F2, F3
  • F1 These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (Galera) effected on July 12, 2026.
  • F2 Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the Merger Agreement), by and among Galera, Obsidian Therapeutics, Inc. (Obsidian), Gazelle Parent, Inc. (Parent), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (Obsidian Merger Sub), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (Galera Merger Sub), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the Galera Merger), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the Mergers).
  • F3 At the effective time of the Galera Merger (the Galera Effective Time), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the Galera Exchange Ratio).
Open filing 0001193125-26-335215 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Alleva Lawrence M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (240) — exercise price 8.20
Disposed (D)240——0Direct (D) No
F1, F2, F4
  • F1 These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (Galera) effected on July 12, 2026.
  • F2 Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the Merger Agreement), by and among Galera, Obsidian Therapeutics, Inc. (Obsidian), Gazelle Parent, Inc. (Parent), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (Obsidian Merger Sub), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (Galera Merger Sub), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the Galera Merger), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the Mergers).
  • F4 At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an In-the-Money Option), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.
Open filing 0001193125-26-335215 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Sussman Joel F. Officer: Chief Accounting Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,000) — exercise price 4.40
Disposed (D)10,000——0Direct (D) No
F1, F2, F3, F4
  • F1 These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (Galera) effected on July 12, 2026.
  • F2 Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the Merger Agreement), by and among Galera, Obsidian Therapeutics, Inc. (Obsidian), Gazelle Parent, Inc. (Parent), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (Obsidian Merger Sub), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (Galera Merger Sub), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the Galera Merger), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the Mergers).
  • F3 At the effective time of the Galera Merger (the Galera Effective Time), each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an In-the-Money Option), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (as defined in Footnote 4) (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.
  • F4 At the Galera Effective Time, each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the Galera Exchange Ratio).
Open filing 0001193125-26-335196 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05FRIEDMAN MICHAEL R. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)41,631——0Indirect (I) See FootnoteNo
F3, F4, F5, F2
  • F3 These numbers have been adjusted to reflect the 1-for-200 reverse stock split (the Reverse Stock Split) Galera Therapeutics, Inc. (Galera) effected on July 12, 2026.
  • F4 Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the Merger Agreement), by and among Galera, Obsidian Therapeutics, Inc. (Obsidian), Gazelle Parent, Inc. (Parent), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (Obsidian Merger Sub), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (Galera Merger Sub), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the Galera Merger), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (the Obsidian Merger and, together with the Galera Merger, the Mergers).
  • F5 At the effective time of the Galera Merger (the Galera Effective Time), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the Galera Exchange Ratio).
  • F2 These securities are held by Equity Trust Company, Custodian FBO Michael Friedman Roth IRA.
Open filing 0001193125-26-335178 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05FRIEDMAN MICHAEL R. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (480) — exercise price 8.20
Disposed (D)480——0Direct (D) No
F3, F4, F6
  • F3 These numbers have been adjusted to reflect the 1-for-200 reverse stock split (the Reverse Stock Split) Galera Therapeutics, Inc. (Galera) effected on July 12, 2026.
  • F4 Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the Merger Agreement), by and among Galera, Obsidian Therapeutics, Inc. (Obsidian), Gazelle Parent, Inc. (Parent), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (Obsidian Merger Sub), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (Galera Merger Sub), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the Galera Merger), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (the Obsidian Merger and, together with the Galera Merger, the Mergers).
  • F6 At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an In-the-Money Option), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.
Open filing 0001193125-26-335178 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05LOKAY KEVIN G Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (240) — exercise price 8.20
Disposed (D)240——0Direct (D) No
F1, F2, F3, F4
  • F1 These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (Galera) effected on July 12, 2026.
  • F2 Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the Merger Agreement), by and among Galera, Obsidian Therapeutics, Inc. (Obsidian), Gazelle Parent, Inc. (Parent), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (Obsidian Merger Sub), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (Galera Merger Sub), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the Galera Merger), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the Mergers).
  • F3 At the effective time of the Galera Merger (the Galera Effective Time), each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an In-the-Money Option), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (as defined in Footnote 4) (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.
  • F4 At the Galera Effective Time, each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the Galera Exchange Ratio).
Open filing 0001193125-26-335228 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Sorensen Mel Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)975——0Direct (D) No
F1, F2, F3
  • F1 These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (Galera) effected on July 12, 2026.
  • F2 Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the Merger Agreement), by and among Galera, Obsidian Therapeutics, Inc. (Obsidian), Gazelle Parent, Inc. (Parent), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (Obsidian Merger Sub), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (Galera Merger Sub), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the Galera Merger), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the Mergers).
  • F3 At the effective time of the Galera Merger (the Galera Effective Time), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the Galera Exchange Ratio).
Open filing 0001193125-26-335499 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Sorensen Mel Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (30,000) — exercise price 4.4
Disposed (D)30,000——0Direct (D) No
F1, F2, F4
  • F1 These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. (Galera) effected on July 12, 2026.
  • F2 Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the Merger Agreement), by and among Galera, Obsidian Therapeutics, Inc. (Obsidian), Gazelle Parent, Inc. (Parent), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent (Obsidian Merger Sub), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (Galera Merger Sub), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the Galera Merger), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the Mergers).
  • F4 At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an In-the-Money Option), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.
Open filing 0001193125-26-335499 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-08-05CHANG NANCY T Director · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)661,309——9,486,852Direct (D) No
F1
  • F1 On February 12, 2026, Galera Therapeutics, Inc. (Galera) filed a Certificate of Amendment (the Amendment) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of Galera's board of directors, Galera may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock (Series B Preferred Stock) into a number of shares of Galera common stock calculated based on the Conversion Ratio (defined as 1,000 shares of Galera common stock issuable upon the conversion of each share of Series B Preferred Stock) (a Mandatory Conversion). On May 15, 2026, Galera effected a Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock had no expiration date.
Open filing 0001193125-26-335224 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-08-05CHANG NANCY T Director · 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (661,309)
Disposed (D)661.3090—0Direct (D) No
F1
  • F1 On February 12, 2026, Galera Therapeutics, Inc. (Galera) filed a Certificate of Amendment (the Amendment) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of Galera's board of directors, Galera may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock (Series B Preferred Stock) into a number of shares of Galera common stock calculated based on the Conversion Ratio (defined as 1,000 shares of Galera common stock issuable upon the conversion of each share of Series B Preferred Stock) (a Mandatory Conversion). On May 15, 2026, Galera effected a Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock had no expiration date.
Open filing 0001193125-26-335224 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-08-05FRIEDMAN MICHAEL R. Director
C

Conversion of derivative security

Common Stock
Acquired (A)2,989,399——8,326,269Indirect (I) See FootnoteNo
F1, F2
  • F1 On February 12, 2026, Galera Therapeutics, Inc. (Galera) filed a Certificate of Amendment (the Amendment) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of Galera's board of directors, Galera may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock (Series B Preferred Stock) into a number of shares of Galera common stock calculated based on the Conversion Ratio (defined as 1,000 shares of Galera common stock issuable upon the conversion of each share of Series B Preferred Stock) (a Mandatory Conversion). On May 15, 2026, Galera effected a Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock had no expiration date.
  • F2 These securities are held by Equity Trust Company, Custodian FBO Michael Friedman Roth IRA.
Open filing 0001193125-26-335178 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-08-05FRIEDMAN MICHAEL R. Director
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (2,989,399)
Disposed (D)2,989.3990—0Indirect (I) See FootnoteNo
F1, F2
  • F1 On February 12, 2026, Galera Therapeutics, Inc. (Galera) filed a Certificate of Amendment (the Amendment) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of Galera's board of directors, Galera may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock (Series B Preferred Stock) into a number of shares of Galera common stock calculated based on the Conversion Ratio (defined as 1,000 shares of Galera common stock issuable upon the conversion of each share of Series B Preferred Stock) (a Mandatory Conversion). On May 15, 2026, Galera effected a Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock had no expiration date.
  • F2 These securities are held by Equity Trust Company, Custodian FBO Michael Friedman Roth IRA.
Open filing 0001193125-26-335178 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-29Emerald Bioventures, LLC 10% ownerOpler Timothy 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)20,813,818——61,029,978Direct (D) No
F1, F3, F2
  • F1 Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock, as amended (Certificate of Designation), no fractional shares were issued upon conversion. In lieu of fractional shares, the Issuer will pay Emerald Bioventures, LLC (Emerald) an amount in cash equal to the trading value of such fractional shares as of the close of business on the date of the conversion in accordance with the Certificate of Designation.
  • F3 Represents 20,813.8186192892 shares of the Issuer's Series B Non Voting Convertible Preferred Stock (the Series B Preferred Stock). On May 15, 2026, the Issuer converted all outstanding Series B Preferred Stock into a number of shares of the Issuer's Common Stock (Common Stock) calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock), pursuant to and in accordance with the Certificate of Designation. The shares of Series B Preferred Stock have no expiration date.
  • F2 This Form 4 is jointly filed by and on behalf of each of Emerald and Timothy Opler. Emerald is the record and direct beneficial owner of the securities reported herein. Mr. Opler is the managing member of Emerald and may be deemed to beneficially own securities owned by Emerald.
Open filing 0001123292-26-000772 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-29Emerald Bioventures, LLC 10% ownerOpler Timothy 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (20,813,818)
Disposed (D)20,813.8186——0Direct (D) No
F3, F1, F2
  • F3 Represents 20,813.8186192892 shares of the Issuer's Series B Non Voting Convertible Preferred Stock (the Series B Preferred Stock). On May 15, 2026, the Issuer converted all outstanding Series B Preferred Stock into a number of shares of the Issuer's Common Stock (Common Stock) calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock), pursuant to and in accordance with the Certificate of Designation. The shares of Series B Preferred Stock have no expiration date.
  • F1 Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock, as amended (Certificate of Designation), no fractional shares were issued upon conversion. In lieu of fractional shares, the Issuer will pay Emerald Bioventures, LLC (Emerald) an amount in cash equal to the trading value of such fractional shares as of the close of business on the date of the conversion in accordance with the Certificate of Designation.
  • F2 This Form 4 is jointly filed by and on behalf of each of Emerald and Timothy Opler. Emerald is the record and direct beneficial owner of the securities reported herein. Mr. Opler is the managing member of Emerald and may be deemed to beneficially own securities owned by Emerald.
Open filing 0001123292-26-000772 Read from the filing’s XML Dispute this row
2026-04-07 Filed 2026-04-09FRIEDMAN MICHAEL R. Director
C

Conversion of derivative security

Common Stock
Acquired (A)5,336,870——5,336,870Indirect (I) See FootnoteNo
F1, F2
  • F1 On February 12, 2026, the Issuer filed a Certificate of Amendment (the Amendment) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of the Issuer's board of directors, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock (Series B Preferred Stock) into a number of shares of Common Stock calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock) (a Mandatory Conversion). On April 7, 2026, the Issuer effected a partial Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock have no expiration date.
  • F2 These securities are held by Equity Trust Company, Custodian FBO Michael Friedman Roth IRA.
Open filing 0000905148-26-001623 Read from the filing’s XML Dispute this row
2026-04-07 Filed 2026-04-09FRIEDMAN MICHAEL R. Director
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (5,336,870)
Disposed (D)5,336.870—2,989.399Indirect (I) See FootnoteNo
F1, F2
  • F1 On February 12, 2026, the Issuer filed a Certificate of Amendment (the Amendment) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of the Issuer's board of directors, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock (Series B Preferred Stock) into a number of shares of Common Stock calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock) (a Mandatory Conversion). On April 7, 2026, the Issuer effected a partial Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock have no expiration date.
  • F2 These securities are held by Equity Trust Company, Custodian FBO Michael Friedman Roth IRA.
Open filing 0000905148-26-001623 Read from the filing’s XML Dispute this row
2026-04-07 Filed 2026-04-09CHANG NANCY T Director · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)1,180,611——8,825,543Direct (D) No
F1
  • F1 On February 12, 2026, the Issuer filed a Certificate of Amendment (the Amendment) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of the Issuer's board of directors, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock (Series B Preferred Stock) into a number of shares of Common Stock calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock) (a Mandatory Conversion). On April 7, 2026, the Issuer effected a partial Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock have no expiration date.
Open filing 0000905148-26-001622 Read from the filing’s XML Dispute this row
2026-04-07 Filed 2026-04-09CHANG NANCY T Director · 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (1,180,611)
Disposed (D)1,180.6110—661.309Direct (D) No
F1
  • F1 On February 12, 2026, the Issuer filed a Certificate of Amendment (the Amendment) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of the Issuer's board of directors, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock (Series B Preferred Stock) into a number of shares of Common Stock calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock) (a Mandatory Conversion). On April 7, 2026, the Issuer effected a partial Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock have no expiration date.
Open filing 0000905148-26-001622 Read from the filing’s XML Dispute this row

Latest reported holdings

What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.

Latest reported holdings
Reporting ownerSecurityShares owned afterDirect or indirectSource
Alleva Lawrence M DirectorStock Option (Right to Buy) Derivative security · underlying Common Stock0D As of 2026-08-03 Open filing 4
Alleva Lawrence M DirectorCommon Stock 0D As of 2026-08-03 Open filing 4
Alleva Lawrence M DirectorCommon Stock 0I By the Lawrence M. Alleva Revocable Trust.As of 2026-08-03 Open filing 4
CHANG NANCY T Director · 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0D As of 2026-05-15 Open filing 4
CHANG NANCY T Director · 10% ownerStock Option (Right to Buy) Derivative security · underlying Common Stock0D As of 2026-08-03 Open filing 4
CHANG NANCY T Director · 10% ownerCommon Stock 0D As of 2026-08-03 Open filing 4
Emerald Bioventures, LLC 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0D As of 2026-05-15 Open filing 4
Emerald Bioventures, LLC 10% ownerCommon Stock 40,216,160D As of 2026-05-04 Open filing 3
Emerald Bioventures, LLC 10% ownerCommon Stock 61,029,978D As of 2026-05-15 Open filing 4
FRIEDMAN MICHAEL R. DirectorSeries B Preferred Stock Derivative security · underlying Common Stock0I See FootnoteAs of 2026-05-15 Open filing 4
FRIEDMAN MICHAEL R. DirectorStock Option (Right to Buy) Derivative security · underlying Common Stock0D As of 2026-08-03 Open filing 4
FRIEDMAN MICHAEL R. DirectorCommon Stock 0I See FootnoteAs of 2026-08-03 Open filing 4
LOKAY KEVIN G DirectorStock Option (Right to Buy) Derivative security · underlying Common Stock0D As of 2026-08-03 Open filing 4
Opler Timothy 10% ownerSeries B Preferred Stock Derivative security · underlying Common Stock0D As of 2026-05-15 Open filing 4
Opler Timothy 10% ownerCommon Stock 40,216,160D As of 2026-05-04 Open filing 3
Opler Timothy 10% ownerCommon Stock 61,029,978D As of 2026-05-15 Open filing 4
Sorensen Mel Director · Officer: President and CEOStock Option (Right to Buy) Derivative security · underlying Common Stock0D As of 2026-08-03 Open filing 4
Sorensen Mel Director · Officer: President and CEOCommon Stock 0D As of 2026-08-03 Open filing 4
Sussman Joel F. Officer: Chief Accounting OfficerStock Option (Right to Buy) Derivative security · underlying Common Stock0D As of 2026-08-03 Open filing 4

Joint filers each report the same shares, so rows are not added together.

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Institutional ownership reported on Form 13F

No percent is shown: the cover-page share count is not available for this company.

  • The lower figure counts positions a manager reports as its own with sole discretion. The upper figure counts every plain-share position and can count a share twice.
  • Neither includes holders that do not file Form 13F, or managers below the filing threshold.
Quarter-by-quarter 13F holders
QuarterManagers holdingShares, at leastShares, at mostFilings read
2026-09-30 0008,935
2026-06-30 0009,178
2026-03-31 193939,173
2025-12-31 0009,222
2025-09-30 0008,469
2025-06-30 0008,516
2025-03-31 0008,518
2024-12-31 0008,580

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read from their tags. Earlier schedules are free text: they are read only when every cover page states a share count and a percent, and the rest are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Ikarian Capital, LLC Common Stock, $0.001 par value per share0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-352953 Dispute this row
Neil Shahrestani Common Stock, $0.001 par value per share0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-352953 Dispute this row
Parvinder Singh Hyare Common stock, par value $0.001 per share (the "Common Stock")6.6513,521,921.0005/15/2026 Filed 2026-06-11SCHEDULE 13DOpen filing 0001104659-26-073025 Dispute this row
Emerald Bioventures, LLC Common stock, par value $0.001 per share (the "Common Stock")30.261,029,97805/15/2026 Filed 2026-05-29SCHEDULE 13D/AAmendment 1Open filing 0001123292-26-000773 Dispute this row
Timothy Opler Common stock, par value $0.001 per share (the "Common Stock")30.261,029,97805/15/2026 Filed 2026-05-29SCHEDULE 13D/AAmendment 1Open filing 0001123292-26-000773 Dispute this row
Emerald Bioventures, LLC Common stock, par value $0.001 per share (the "Common Stock")26.540,216,16004/07/2026 Filed 2026-04-27SCHEDULE 13DOpen filing 0001123292-26-000583 Dispute this row
Timothy Opler Common stock, par value $0.001 per share (the "Common Stock")26.540,216,16004/07/2026 Filed 2026-04-27SCHEDULE 13DOpen filing 0001123292-26-000583 Dispute this row
CHANG NANCY T Common stock, $0.001 par value per share5.98,921,54312/30/2024 Filed 2026-04-10SCHEDULE 13DOpen filing 0000905148-26-001633 Dispute this row
Yair Schneid COMMON STOCK19.9010,823,610— Filed 2024-05-16SC 13G/AAmendment 2Read from the cover page textOpen filing 0001213900-24-044071 Dispute this row
Alpha Pharma Investments LLC COMMON STOCK10.8995,928,137— Filed 2024-05-16SC 13GRead from the cover page textOpen filing 0001213900-24-044069 Dispute this row
Rochel Soffer COMMON STOCK10.8995,928,137— Filed 2024-05-16SC 13GRead from the cover page textOpen filing 0001213900-24-044069 Dispute this row
Yair Schneid COMMON STOCK19.9010,823,610— Filed 2024-05-01SC 13G/AAmendment 1Read from the cover page textOpen filing 0001213900-24-038572 Dispute this row
Yair Schneid COMMON STOCK13.0737,110,801— Filed 2024-01-17SC 13GRead from the cover page textOpen filing 0001213900-24-003834 Dispute this row
GSA Capital Partners LLP (Name of Issuer) : Galera Therapeutics ORD7.1563,892,561— Filed 2024-01-02SC 13GRead from the cover page textOpen filing 0001362033-24-000001 Dispute this row
Clarus IV-A, L.P. Common Stock, par value $0.001 per share1.0542,555— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Clarus IV-B, L.P. Common Stock, par value $0.001 per share0.7353,661— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Clarus IV-C, L.P. Common Stock, par value $0.001 per share1.2652,324— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Clarus IV-D, L.P. Common Stock, par value $0.001 per share0.2130,444— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Clarus IV Galera Royalty AIV, L.P. Common Stock, par value $0.001 per share1.0550,661— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Clarus IV GP, L.P. Common Stock, par value $0.001 per share4.12,229,645— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Blackstone Clarus GP L.P. Common Stock, par value $0.001 per share4.12,229,645— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Blackstone Clarus GP L.L.C. Common Stock, par value $0.001 per share4.12,229,645— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Blackstone Holdings I L.P. Common Stock, par value $0.001 per share4.12,229,645— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Blackstone Holdings I/II GP L.L.C. Common Stock, par value $0.001 per share4.12,229,645— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Blackstone Inc. Common Stock, par value $0.001 per share4.22,289,605— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Blackstone Group Management L.L.C. Common Stock, par value $0.001 per share4.22,289,605— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Stephen A. Schwarzman Common Stock, par value $0.001 per share4.22,289,605— Filed 2023-12-04SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-288420 Dispute this row
Altamont Pharmaceutical Holdings, LLC Common Stock12.025,280,000— Filed 2023-11-13SC 13GRead from the cover page textOpen filing 0001104659-23-117077 Dispute this row
Mark Pearson Common Stock12.025,280,000— Filed 2023-11-13SC 13GRead from the cover page textOpen filing 0001104659-23-117077 Dispute this row
Novo Holdings A/S Common Stock, $0.001 par value per share4.92,100,000— Filed 2023-06-28SC 13G/AAmendment 4Read from the cover page textOpen filing 0001193125-23-177520 Dispute this row
Deerfield Mgmt, L.P. Common Stock4.992,916,401— Filed 2023-02-28SC 13GRead from the cover page textOpen filing 0001193805-23-000248 Dispute this row
Deerfield Management Company, L.P. Common Stock4.992,916,401— Filed 2023-02-28SC 13GRead from the cover page textOpen filing 0001193805-23-000248 Dispute this row
Deerfield Partners, L.P. Common Stock4.992,916,401— Filed 2023-02-28SC 13GRead from the cover page textOpen filing 0001193805-23-000248 Dispute this row
James E. Flynn Common Stock4.992,916,401— Filed 2023-02-28SC 13GRead from the cover page textOpen filing 0001193805-23-000248 Dispute this row
Sectoral Asset Management Inc COMMON STOCK5.81,666,666— Filed 2023-02-13SC 13GRead from the cover page textOpen filing 0001104659-23-019589 Dispute this row
Jérôme G. Pfund COMMON STOCK5.81,666,666— Filed 2023-02-13SC 13GRead from the cover page textOpen filing 0001104659-23-019589 Dispute this row
Michael L. Sjöström COMMON STOCK5.81,666,666— Filed 2023-02-13SC 13GRead from the cover page textOpen filing 0001104659-23-019589 Dispute this row
Clarus IV-A, L.P. Common Stock, par value $0.001 per share1.9542,555— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Clarus IV-B, L.P. Common Stock, par value $0.001 per share1.2353,661— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Clarus IV-C, L.P. Common Stock, par value $0.001 per share2.3652,324— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Clarus IV-D, L.P. Common Stock, par value $0.001 per share0.5130,444— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Clarus IV Galera Royalty AIV, L.P. Common Stock, par value $0.001 per share1.9550,661— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Clarus IV GP, L.P. Common Stock, par value $0.001 per share7.72,229,645— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Blackstone Clarus GP L.P. Common Stock, par value $0.001 per share7.72,229,645— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Blackstone Clarus GP L.L.C. Common Stock, par value $0.001 per share7.72,229,645— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Blackstone Holdings I L.P. Common Stock, par value $0.001 per share7.72,229,645— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Blackstone Holdings I/II GP L.L.C. Common Stock, par value $0.001 per share7.72,229,645— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Blackstone Inc. Common Stock, par value $0.001 per share7.82,274,605— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Blackstone Group Management L.L.C. Common Stock, par value $0.001 per share7.82,274,605— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row
Stephen A. Schwarzman Common Stock, par value $0.001 per share7.82,274,605— Filed 2023-02-09SC 13DRead from the cover page textOpen filing 0001193125-23-030224 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

3,104,499 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015258,595
2016246,472
2017244,814
2018245,575
2019238,619
2020249,093
2021274,850
2022257,922
2023253,676
2024261,106
2025235,525
2026263,830

Filings made before the SEC required XML are listed, not extracted.

Back to GALERA THERAPEUTICS, INC.